Onyx Biolabs score history
Every recorded change to Onyx Biolabs’s overall score since October 18, 2026, with the audit note written at the time. Scores follow our published methodology; affiliate status never affects them.
- Score today
- 7.29/10
Score today
- Score changes
- 15
Score changes
- Audit entries
- 15
Audit entries
Score over time
Every entry newest first
- Lowered from7.30to7.29(-0.01)
Market medians updated after Snowman Research was added pricing 8.0 to 7.9.
- Raised from7.29to7.30(+0.01)
Market medians updated after Stack Research was added pricing 7.9 to 8.0.
- Lowered from7.30to7.29(-0.01)
Market medians updated after Bluum Peptides was added pricing 8.0 to 7.9.
- Raised from7.29to7.30(+0.01)
Pricing recomputed on 27 October 2026: listings added for a newly reviewed vendor (Peptide Pro) moved the market median for the same products pricing 7.9 to 8.0.
- Lowered from7.30to7.29(-0.01)
Pricing recomputed on 26 October 2026: listings added for a newly reviewed vendor (StudzPeptides) moved the market median for the same products: pricing 8.0 to 7.9.
- Raised from7.29to7.30(+0.01)
Pricing recomputed on 26 October 2026: a vendor was removed from the directory, which moved the market median for the same products: pricing 7.9 to 8.0.
- Lowered from7.30to7.29(-0.01)
Pricing recomputed on 26 October 2026: listings added for a newly reviewed vendor (Lotus Peptide) moved the market median for the same products: pricing 8.0 to 7.9.
- Lowered from7.32to7.30(-0.02)
Pricing recomputed on 25 October 2026: listings added for a newly reviewed vendor (Pexo Labs) moved the market median for the same products: pricing 8.1 to 8.0.
- Lowered from7.33to7.32(-0.01)
Pricing recomputed on 24 October 2026 after Bionova Peptides' first-review prices were recorded; other vendors move only through the market medians: pricing 8.2 to 8.1.
- Raised from7.29to7.33(+0.04)
Operating history re-checked on 22 October 2026 under the published rule (earliest dated evidence of the business, including a never-parked store domain and the named operating company, looked up for every vendor): operating history 1.4 to 2.2.
- Raised from7.24to7.29(+0.05)
Re-scored on 22 October 2026 under version 2 of our published rules. AOD-9604's printed Kovera report number was confirmed at the laboratory (the number we had stored was the file name in a broken link on the vendor's results card). Lab 7.7 to 7.8. Score 7.24 to 7.29.
- Raised from6.96to7.24(+0.28)
Re-scored on 22 October 2026 under our published rubric for shipping, pricing, operating history and transparency, applied to every vendor the same day: prices re-read from the vendor's site and matched by milligrams per vial, operating history from the earliest dated evidence of the business, and policies scored item by item. shipping and refunds 5.5 to 7.0, transparency 6.5 to 6.0.
- Lowered from7.07to6.96(-0.11)
Re-scored on 22 October 2026 under our published rubric for shipping, pricing, operating history and transparency, applied to every vendor the same day: prices re-read from the vendor's site and matched by milligrams per vial, operating history from the earliest dated evidence of the business, and policies scored item by item. pricing 8.6 to 8.2, operating history 2.3 to 1.4.
- Lowered from7.12to7.07(-0.05)
Lab score recalculated on 22 October 2026 under the uniform published rubric applied to every vendor: every listed product was rescored on the same fixed certificate points, with fixed deductions for site statements about testing that the certificates do not bear out. Lab 7.8 to 7.7.
- Lowered from7.30to7.12(-0.18)
Re-audit, read through a customer account because the catalog, prices, certificates and policies are now behind registration. Lab rises from 7.23 to 7.8: 75 of 76 Kovera reports were verified in the laboratory's records, covering nearly every product, many with endotoxin and heavy-metal screens; there is no sterility testing and the AOD-9604 entry could not be verified. Shipping falls from 7.2 to 5.5 because all sales are final, the damage window is 48 hours, and lost or misdelivered parcels are covered only with paid insurance. Pricing moves from 9.5 to 8.6 on live selling prices about 22% below the market, with a small deduction because every product is shown against a struck-through regular price. Tenure 2.0 to 2.3 and transparency 7.2 to 6.5: the operating company and address are named, but the catalog and certificates are no longer public.
Score changes for every vendor are on the score changes page. Onyx Biolabs may display its current score with the score badge, which updates automatically and has no effect on the score.